Asim Mohammed, MD
Advanced Heart Failure and Transplant Cardiology · Fort Wayne, INNPI 1922285139
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,025 of the $117,745 with a category attached, or 71.4%. 20 manufacturers reported payments, led by Abiomed at 43.5% of the total. Reporting peaked in 2019 at $59,851 and has fallen 99.4% since, to $386 in 2025.
Across 207 payments — averaging $568.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$51K
- Novartis$47K
- Abbott$8K
- AstraZeneca$7K
- Merck$4K
- Medtronic$288
- plus $763 from 14 others
Across 2 payments — averaging $18,373 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$37K
What the payments were for
- Consulting fees$10,4759%
- Speaking & faculty fees$84,02571%
- Travel & lodging$17,27915%
- Food & beverage$5,8605%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 34 | $51,263 |
| Novartis | 48 | $47,443 |
| Abbott | 72 | $7,838 |
| AstraZeneca | 18 | $6,583 |
| Merck | 6 | $3,568 |
| Medtronic | 3 | $288 |
| Impulse Dynamics (USA) Inc. | 4 | $182 |
| United Therapeutics Corporation | 3 | $122 |
| Lexicon Pharmaceuticals, Inc. | 1 | $121 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 1 | $44 |
| Boston Scientific | 2 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $37 |
| Cvrx, Inc. | 2 | $29 |
| Pfizer | 2 | $28 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Livanova USA, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$50,914
- ENTRESTO$40,093
- VERQUVO$7,036
- FARXIGA$6,277
- CardioMEMS HF System$2,129
- CARDIOMEMS$1,655
- HeartMate 3 Left Ventricular Dev$1,300
- HeartMate 3 Left Ventricular Assist Device$1,010
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$428
- HeartWare HVAD$271
- Inpefa$121
How this compares
$117,745 in reported general payments places this provider in the 85th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.
See all advanced heart failure and transplant cardiology providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Fort Wayne
- Mark JonesFort Wayne$1K
- Sasikanth AdigopulaIndianapolis$310K
- Ashwin RavichandranIndianapolis$284K
- Rafael Garcia-CortesIndianapolis$101K
- Thomas SchleeterAnderson$50K
- Amit PatelIndianapolis$41K
- Sunit-Preet ChaudhryIndianapolis$27K
- Radha KannegantiIndianapolis$18K
- Mary WalshIndianapolis$17K
- Bhavana Siddegowda-BangaloreIndianapolis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.